Category: Oral Medication

Lilly - Boehringer - logo

New Studies Evaluating Tradjenta, Type 2 Diabetes Treatment

Eli Lilly and Boehringer Ingelheim presented results from two randomized phase 3 clinical trials and a post-hoc analysis for linagliptin, marketed under the name Tradjenta in the U.S, at the American Diabetes Association's (ADA) 72nd Scientific Sessions. The new studies...
0 Shares
Metformin Recalls: What You Need to Know

Diabetes and Cancer: Can Metformin Treat Both?

The association between diabetes and cancer was first noted over 100 years ago, but physicians have become increasingly aware of this association only in the last few years as recent studies have demonstrated that having diabetes increases the risk of almost all types of cancer. The risk of pancreatic, liver, and endometrial cancer is approximately twice that of the non-diabetic population. Some studies have reported a similar increase in the risk of bladder cancer and in cancers of the oral cavity.
0 Shares
gsk-logo

Children with Type 2 Diabetes do Better with Avandia

The results of a randomized clinical trial funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in children with type 2 diabetes show that children and adolescents treated with a combination of metformin and Avandia (rosiglitazone) had better glycemic control than children....
0 Shares
takeda_logo

FDA Requests More Data on Takeda’s Alogliptin

The FDA has issued a complete response letter to Japanese drug-maker Takeda Pharmaceutical regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone...
0 Shares
Bristol-Myers Logo

Experimental Diabetes Drug Shows Improved Glycemic Control

A new study evaluating the efficacy and safety of adding dapagliflozin therapy to the treatment of type 2 diabetes patients whose blood glucose levels remain poorly controlled despite high doses of insulin was published today in the Annuls of Internal Medicine...
0 Shares
merck logo

FDA Approves Merck’s New Type 2 Diabetes Drug Janumet

The FDA has approved Merck's (MSD) new type 2 diabetes medication, JANUMET(R) XR (sitagliptin and metformin hydrochloride (HCl) extended-release) The new treatment combines sitagliptin, which is the active component of Januvia (sitagliptin), with extended-release metformin...
0 Shares